Bayer Warned of Essure Complaint Rise Long Before Sales Halt (3)

Aug. 20, 2020, 9:28 AM

A Bayer AG official warned the company of increased government scrutiny of injuries from its Essure contraceptive implant years before it was pulled from the market, according to recently unsealed court documents.

Four months after Bayer bought the maker of Essure for $1 billion in 2013, a senior manager of product surveillance, Michael Reddick, said in an email the company would see “a large increase in the number of (side-effect reports) filed” that “will certainly be noticed” by the U.S. Food and Drug Administration.

Litigation involving Essure has added to the German company’s woes as it wrestles with the fallout ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.